Navigating Sequencing in Relapsed/Refractory Multiple Myeloma: Canadian Experts Discuss the Evidence and the Evolving Options

Authors

  • Peter Anglin, MD, MBA, FRCPC Physician Lead Stronach Regional Cancer Centre and Central LHIN Regional Cancer Program
  • Paola Neri, MD, PhD Associate Professor, Cumming School of Medicine, University of Calgary, Calgary, AB
  • Joshua Richter, MD, FACP Associate Professor of Medicine, Tisch Cancer Institute, NY, NY Director of Multiple Myeloma, Blavatnik Family- Chelsea Medical Center, Mount Sinai Hospital, NY, NY
  • Darrell White, MD, MSc, FRCPC, FACP Professor of Medicine, Dalhousie University Halifax, NS

DOI:

https://doi.org/10.58931/cht.2026.5s0181

Abstract

Relapsed and refractory (R/R) multiple myeloma presents increasingly complex therapeutic decisions. Clinicians must not only weigh efficacy and tolerability but consider how today’s treatment decisions will affect future options. In a roundtable discussion, myeloma experts discuss practical approaches to sequencing therapies across diverse patient scenarios.

Author Biographies

Peter Anglin, MD, MBA, FRCPC, Physician Lead Stronach Regional Cancer Centre and Central LHIN Regional Cancer Program

Dr. Peter Anglin’s clinical focus remains in haematologic and lymphoid malignancies. He is currently Physician Lead for the Stronach Regional Cancer Centre in Newmarket, Ontario. He has also developed an interest in health systems delivery, process redesign in the ambulatory setting, and optimizing drug access for oncology patients. He continues to serve in an advisory capacity to a number of pharmaceutical and health-related organizations. He remains the medical director of CarePath, a cancer navigation and support service supporting Cancer Care Ontario and Ontario cancer patients.

Paola Neri, MD, PhD, Associate Professor, Cumming School of Medicine, University of Calgary, Calgary, AB

Paola Neri is an Associate Professor of Medicine, attending physician in the Hematology division at University of Calgary and member of the Arnie Charbonneau Cancer Institute. Since January 2019, she has been the Scientific Director of the Cancer Translational Research Core, a clinically accredited laboratory located at the Arthur Child Comprehensive Cancer Center in Calgary. Dr. Neri received her medical degree at Magna Græcia University, Catanzaro, Italy in 2000. She completed her specialty in Medical Oncology at Magna Græcia University, Catanzaro, Italy in 2005 and received a PhD in Molecular Oncology and Experimental Immunology in 2011. From 2003-2006 she was Research Associate at Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA under the mentorship of Dr. Kenneth Anderson. In June 2008, she joined the University of Calgary. The main focus of her research is the study of multiple myeloma (MM) with a particular interest in genomic studies with the goal of identifying mechanisms of drug resistance and discovering novel therapeutic targets for this incurable disease. Dr. Neri is well published in the field and received national and international grants from several agencies including International Myeloma Society, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation and Canadian Institute of Health Research (CIHR). In 2019 she received the Engineered Air Chair (research funds) in Cancer Research from University of Calgary. In 2021 she was selected by the International Myeloma Society to receive the Ken Anderson Young Investigator Award for her important translational work in multiple myeloma. In 2025 she has received the Global Impact in Myeloma Research Award from the Canadian Myeloma Research Group (CMRG). She is currently member of the American Society of Hematology, co-chair of Charbonneau Research & Innovation Committee in Calgary and member of Blood Editorial Board, very active both in preclinical and clinical trial research in Myeloma.

Joshua Richter, MD, FACP , Associate Professor of Medicine, Tisch Cancer Institute, NY, NY Director of Multiple Myeloma, Blavatnik Family- Chelsea Medical Center, Mount Sinai Hospital, NY, NY

Joshua Richter is an Associate Professor of Medicine, Hematology and Oncology in the Myeloma Division at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai and the Director of Myeloma at the Blavatnik Family Chelsea Medical Center at Mount Sinai. He completed undergraduate work at Johns Hopkins University and subsequently went on to medical school at New York Medical College. He completed residency at St. Vincent’s Hospital – New York Medical College. Dr. Richter completed his hematology/oncology fellowship at the Yale Cancer Center. After completing fellowship, he worked in the myeloma division at the John Theurer Cancer Center at Hackensack University Medical. In 2018 he joined the Myeloma Division at Mount Sinai Hospital. Dr. Richter has been published in numerous oncology journals including NEJM, Blood, and the Journal of Clinical Oncology. He has an interest in immunotherapy, multi-functional antibodies and precision medicine.

Darrell White, MD, MSc, FRCPC, FACP , Professor of Medicine, Dalhousie University Halifax, NS

Dr. Darrell White is a Professor of Medicine in the Faculty of Medicine, Dalhousie University and a hematologist at the Queen Elizabeth II Health Sciences Centre in Halifax, Nova Scotia. Dr. White is a graduate of Dalhousie Medical School, trained in Internal Medicine at the University of Western Ontario and in Hematology at Dalhousie. He completed a fellowship at the Myeloma and Transplantation Research Center at the University of Arkansas. He has completed graduate studies in Community Health and Epidemiology at Dalhousie. Since 1998 he has been a member of the Division of Hematology, Department of Medicine at the Queen Elizabeth II Health Sciences Center in Halifax. His research interest and clinical practice focus on management of multiple myeloma. He is the past Senior Associate Dean in the Faculty of Medicine, Dalhousie University, a past chair of the Royal College Specialty Committee in Hematology and past Royal College examiner in internal medicine and hematology. He is a current examiner for hematology with the Canadian Royal College International and the current Board Chair for the Canadian Myeloma Research Group.

Downloads

Published

2026-02-03

How to Cite

1.
Anglin P, Neri P, Richter J, White D. Navigating Sequencing in Relapsed/Refractory Multiple Myeloma: Canadian Experts Discuss the Evidence and the Evolving Options. Can Hematol Today [Internet]. 2026 Feb. 3 [cited 2026 Feb. 4];5(s01):2–9. Available from: https://canadianhematologytoday.com/article/view/5-s01-Anglin_et_al

Issue

Special Supplement, Winter 2026

Section

Articles

License

Copyright (c) 2026 Canadian Hematology Today

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.